R
Robbert J. van Alphen
Publications - 18
Citations - 990
Robbert J. van Alphen is an academic researcher. The author has contributed to research in topics: Pharmacokinetics & Tamoxifen. The author has an hindex of 8, co-authored 15 publications receiving 881 citations.
Papers
More filters
Journal Article
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
Ron H.J. Mathijssen,Robbert J. van Alphen,Jaap Verweij,Walter J. Loos,Kees Nooter,Gerrit Stoter,Alex Sparreboom +6 more
TL;DR: CPT-11 belongs to the class of topoisomerase I inhibitors, and it acts as a prodrug of SN-38, which is approximately 100-1000fold more cytotoxic than the parent drug as mentioned in this paper.
Journal ArticleDOI
Pharmacokinetic, Metabolic, and Pharmacodynamic Profiles in a Dose-Escalating Study of Irinotecan and Cisplatin
Maja J.A. de Jonge,Jaap Verweij,Peter de Bruijn,Eric Brouwer,Ron H.J. Mathijssen,Robbert J. van Alphen,Maureen M. de Boer-Dennert,Laurent Vernillet,Christian Jacques,Alex Sparreboom +9 more
TL;DR: There was no apparent pharmacokinetic interaction between irinotecan and cisplatin in this study and linear pharmacokinetics comparable to that observed with single-agent administration suggests an absence of pharmacokinetically interaction.
Journal ArticleDOI
Dextromethorphan As a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment
Anne-Joy M. de Graan,S.F. Teunissen,Filip Y.F.L. de Vos,Walter J. Loos,Ron H.N. van Schaik,Felix E. de Jongh,Aad I. de Vos,Robbert J. van Alphen,Bronno van der Holt,Jaap Verweij,Caroline Seynaeve,Jos H. Beijnen,Ron H.J. Mathijssen +12 more
TL;DR: Dextromethorphan exposure after a single administration adequately predicted endoxifen exposure in individual patients with breast cancer taking tamoxifens, but it needs additional validation and simplification before being applicable in future dosing strategies.
Journal ArticleDOI
Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients.
Lisette Binkhorst,Lisette Binkhorst,Jacqueline S. L. Kloth,Annelieke S. de Wit,Peter de Bruijn,Mei H. Lam,Inês Chaves,Herman Burger,Robbert J. van Alphen,P. Hamberg,Ron H.N. van Schaik,Agnes Jager,Birgit C. P. Koch,Erik A.C. Wiemer,Teun van Gelder,Gijsbertus T. J. van der Horst,Ron H.J. Mathijssen +16 more
TL;DR: The results suggest that dosing time is of marginal influence on tamoxifen pharmacokinetics, and circadian rhythm may be one of the many determinants of the interpatient and intrapatient pharmacokinetic variability of tamoxIFen.
Journal ArticleDOI
Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen.
Koen G A M Hussaarts,Daan P. Hurkmans,Esther Oomen-de Hoop,Leonie J van Harten,Stan Berghuis,Robbert J. van Alphen,Leontine E.A. Spierings,Quirine C. van Rossum-Schornagel,Mijntje B. Vastbinder,Ron H.N. van Schaik,Teun van Gelder,Agnes Jager,Roelof W F van Leeuwen,Ron H.J. Mathijssen +13 more
TL;DR: Co-treatment with curcumin could lower endoxifen concentrations below the threshold for efficacy (potentially 20–40% of the patients), especially in EM patients, because of the effects of CYP2D6 metabolism phenotype.